메타비아 (MTVA) 주가

메타비아(MTVA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.67 (+5.03%), 시가총액 $0.01B, 52주 최저~최고 $0.60 ~ $11.52.

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietar

핵심 지표

• 현재가: $1.67 (+5.03%)
• 시가총액: $0.01B
• 52주 최저~최고: $0.60 ~ $11.52
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

메타비아의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

메타비아 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.64
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문